352 related articles for article (PubMed ID: 32331832)
1. Approach to Diagnosis and Management of Primary Glomerular Diseases Due to Podocytopathies in Adults: Core Curriculum 2020.
Ahn W; Bomback AS
Am J Kidney Dis; 2020 Jun; 75(6):955-964. PubMed ID: 32331832
[TBL] [Abstract][Full Text] [Related]
2. In situ evaluation of podocytes in patients with focal segmental glomerulosclerosis and minimal change disease.
da Silva CA; Monteiro MLGDR; Araújo LS; Urzedo MG; Rocha LB; Dos Reis MA; Machado JR
PLoS One; 2020; 15(11):e0241745. PubMed ID: 33147279
[TBL] [Abstract][Full Text] [Related]
3. Ultrastructural features and expression of cytoskeleton proteins of podocyte from patients with minimal change disease and focal segmental glomerulosclerosis.
Shi SF; Wang SX; Zhang YK; Zhao MH; Zou WZ
Ren Fail; 2008; 30(5):477-83. PubMed ID: 18569926
[TBL] [Abstract][Full Text] [Related]
4. Immunoexpression of podocyte-associated proteins in acquired human glomerulopathies with nephrotic syndrome.
Wagrowska-Danilewicz M; Stasikowska O; Danilewicz M
Pol J Pathol; 2006; 57(1):17-21. PubMed ID: 16739878
[TBL] [Abstract][Full Text] [Related]
5. AMPK mediates regulation of glomerular volume and podocyte survival.
Banu K; Lin Q; Basgen JM; Planoutene M; Wei C; Reghuvaran AC; Tian X; Shi H; Garzon F; Garzia A; Chun N; Cumpelik A; Santeusanio AD; Zhang W; Das B; Salem F; Li L; Ishibe S; Cantley LG; Kaufman L; Lemley KV; Ni Z; He JC; Murphy B; Menon MC
JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34473647
[TBL] [Abstract][Full Text] [Related]
6. New Anti-Nephrin Antibody Mediated Podocyte Injury Model Using a C57BL/6 Mouse Strain.
Takeuchi K; Naito S; Kawashima N; Ishigaki N; Sano T; Kamata K; Takeuchi Y
Nephron; 2018; 138(1):71-87. PubMed ID: 28965116
[TBL] [Abstract][Full Text] [Related]
7. Indications for kidney biopsy in idiopathic childhood nephrotic syndrome.
Alshami A; Roshan A; Catapang M; Jöbsis JJ; Kwok T; Polderman N; Sibley J; Sibley M; Mammen C; Matsell DG;
Pediatr Nephrol; 2017 Oct; 32(10):1897-1905. PubMed ID: 28540445
[TBL] [Abstract][Full Text] [Related]
8. [Ultrastructural study of podocyte alterations in non proliferative glomerulopathy].
Sipovsky VG; Nevorotin AI; Avsiewitsch IV; Smirnov AV
Arkh Patol; 2019; 81(3):51-58. PubMed ID: 31317931
[TBL] [Abstract][Full Text] [Related]
9. Podocyte and endothelial injury in focal segmental glomerulosclerosis: an ultrastructural analysis.
Taneda S; Honda K; Ohno M; Uchida K; Nitta K; Oda H
Virchows Arch; 2015 Oct; 467(4):449-58. PubMed ID: 26266776
[TBL] [Abstract][Full Text] [Related]
10. Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum.
Stokes MB; Markowitz GS; Lin J; Valeri AM; D'Agati VD
Kidney Int; 2004 May; 65(5):1690-702. PubMed ID: 15086908
[TBL] [Abstract][Full Text] [Related]
11. Urinary podocytes in primary focal segmental glomerulosclerosis.
Hara M; Yanagihara T; Kihara I
Nephron; 2001 Nov; 89(3):342-7. PubMed ID: 11598401
[TBL] [Abstract][Full Text] [Related]
12. [Minimal change disease and focal segmental glomerulosclerosis].
Müller-Deile J; Schenk H; Schiffer M
Internist (Berl); 2019 May; 60(5):450-457. PubMed ID: 30887070
[TBL] [Abstract][Full Text] [Related]
13. Cell-cycle regulatory proteins in the podocyte in collapsing glomerulopathy in children.
Srivastava T; Garola RE; Singh HK
Kidney Int; 2006 Aug; 70(3):529-35. PubMed ID: 16775597
[TBL] [Abstract][Full Text] [Related]
14. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?
Novelli R; Gagliardini E; Ruggiero B; Benigni A; Remuzzi G
Am J Physiol Renal Physiol; 2016 Mar; 310(5):F335-41. PubMed ID: 26697986
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of anti-nephrin antibodies in podocytopaties among adults.
Chebotareva N; Vinogradov A; Birukova Y; Alentov I; Sergeeva N; Chemodanova D; Kononikhin AS; Moiseev SV
Nephrology (Carlton); 2024 Feb; 29(2):86-92. PubMed ID: 37864506
[TBL] [Abstract][Full Text] [Related]
16. Assessment of urinary angiotensinogen as a marker of podocyte injury in proteinuric nephropathies.
Eriguchi M; Yotsueda R; Torisu K; Kawai Y; Hasegawa S; Tanaka S; Noguchi H; Masutani K; Kitazono T; Tsuruya K
Am J Physiol Renal Physiol; 2016 Feb; 310(4):F322-33. PubMed ID: 26632605
[TBL] [Abstract][Full Text] [Related]
17. Spectrum of podocytopathies in new-onset nephrotic syndrome following COVID-19 disease: a report of 2 cases.
Gupta RK; Bhargava R; Shaukat AA; Albert E; Leggat J
BMC Nephrol; 2020 Aug; 21(1):326. PubMed ID: 32753052
[TBL] [Abstract][Full Text] [Related]
18. Pathobiology of focal segmental glomerulosclerosis: new developments.
D'Agati VD
Curr Opin Nephrol Hypertens; 2012 May; 21(3):243-50. PubMed ID: 22357339
[TBL] [Abstract][Full Text] [Related]
19. Morphologic Analysis of Urinary Podocytes in Focal Segmental Glomerulosclerosis.
Shirai Y; Miura K; Yokoyama T; Horita S; Nakayama H; Seino H; Ando T; Shiratori A; Yabuuchi T; Kaneko N; Ishiwa S; Ishizuka K; Hara M; Hattori M
Kidney360; 2021 Mar; 2(3):477-486. PubMed ID: 35369007
[TBL] [Abstract][Full Text] [Related]
20. Potential Urine Proteomic Biomarkers for Focal Segmental Glomerulosclerosis and Minimal Change Disease.
Chebotareva NV; Vinogradov A; Brzhozovskiy AG; Kashirina DN; Indeykina MI; Bugrova AE; Lebedeva M; Moiseev S; Nikolaev EN; Kononikhin AS
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
